High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)

The National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), has reissued a critical Notice of Funding Opportunity (NOFO) titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)." This funding opportunity is aimed at supporting high-impact research situated at the intersection of HIV and substance use. With the HIV epidemic persisting among populations who use addictive substances, and the complexities introduced by comorbidities and care disparities, the NIH seeks to foster research that advances prevention, treatment, and potential cures for HIV in these vulnerable populations. The initiative is aligned with the NIH HIV/AIDS Research Priorities and underscores the agency’s broader strategic goal of reducing the impact of HIV/AIDS, especially in communities burdened by substance use disorders (SUDs). This program encourages both individual investigators and interdisciplinary research teams to submit proposals, with the potential to stimulate novel areas of inquiry or deliver impactful advancements in existing research tracks. Eligible projects may span basic science, epidemiology, clinical trials, intervention studies, and implementation research. A crucial requirement is that all proposals must present a detailed research plan, include preliminary data, and clearly articulate the linkage to substance use. NIDA’s HIV research priorities inform the focus areas, which include preventing new infections, understanding the pathogenesis of HIV in people with SUDs, addressing comorbidities, and improving health outcomes. Applications should align with these thematic areas and seek to accelerate scientific discoveries at this critical nexus. A wide range of research topics is supported under this NOFO, including studies on stigma reduction, social determinants of health, and disparities in healthcare access. Other supported areas involve modeling HIV risk, integrating HIV care with overdose prevention services, biomedical strategies, and approaches for ART-free remission. Applications may also propose novel data modeling techniques, studies focused on women and girls—especially women of color with SUDs—and optimization of care strategies for aging populations. Projects examining neurocognitive impacts, immune response modulation, and latent reservoirs in the CNS are also encouraged, with special consideration for leveraging existing NIDA-funded resources like the PhenX Toolkit and longitudinal cohort studies. The total program funding is anticipated at $3 million per year for FY 2025 through FY 2027, with an expected 3–5 awards issued annually. Application budgets are not capped but must be commensurate with the scope and scale of the proposed research. The maximum project period is five years. There is no cost-sharing requirement, and both domestic and foreign organizations are eligible. Eligible applicants include a comprehensive list of institutional types: institutions of higher education, nonprofits, for-profit entities, local and state governments, and Native American tribal organizations. Foreign components and foreign organizations may also apply. Applications will be accepted via Grants.gov and eRA Commons using the NIH ASSIST platform or institutional system-to-system solutions. Applicants must follow the NIH Application Guide closely and ensure that all required registrations—including SAM, eRA Commons, and Grants.gov—are complete well in advance of the submission deadline. Letters of intent are due 30 days before the application due dates, which for AIDS-related submissions recur multiple times, including on February 11, 2025; August 13, 2025; February 11, 2026; and onward through February 5, 2027. All applications are due by 5:00 PM local time of the applicant organization. There are no exceptions for late submissions. Evaluation criteria emphasize the importance of research significance, innovation, scientific rigor, feasibility, and investigator qualifications. Each application will undergo NIH's peer review process, including a scientific merit review followed by an advisory council review. Reviewers will assess the scientific quality, relevance to NIH’s HIV/AIDS priorities, feasibility, and the capacity of the applicant institution. Final award decisions will also consider program priorities and availability of funds. Successful applicants can anticipate earliest start dates between December and April depending on the review cycle. This NOFO is scheduled to expire on March 6, 2027, as per the latest update from NIH.

Ensure alignment with NIH HIV/AIDS research priorities and provide strong rationale and preliminary data. Emphasize scientific rigor and feasibility.